Dynamic Changes in Inflammatory Biomarkers and Their Correlation with Therapeutic Response in Breast Cancer Patients Undergoing Chemotherapy

Document Type : Original Article

Authors

1 Associate Professor of Radiology, Department of Radiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

2 Assistant Professor of Pathology, Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

10.5281/zenodo.23125761
Abstract
Introduction: Systemic inflammation significantly influences breast cancer therapeutic efficacy; however, static baseline assessments often fail to capture dynamic treatment responses. Longitudinal monitoring of hematologic inflammatory indices may provide a more robust surrogate for real-time chemosensitivity. Therefore, this study investigates dynamic changes in inflammatory biomarkers during chemotherapy and evaluates their association with objective therapeutic response in breast cancer patients.

Material and methods: This descriptive cross-sectional study at Imam Reza Hospital (Tabriz) enrolled 125 participants via convenience sampling, determined using the Cochran formula. Investigators systematically extracted comprehensive demographic, clinical, laboratory, and histopathological data from medical records. Statistical analyses assessed variable associations, ensuring all procedures strictly adhered to institutional ethical guidelines and the Declaration of Helsinki.

Results: Baseline systemic inflammation inversely correlates with chemosensitivity (P < 0.001). Responders demonstrated significant downward kinetics, whereas non-responders maintained elevated inflammatory burdens throughout therapy. A multivariable combined predictive model significantly outperformed individual biomarkers (AUC 0.912, 95% CI 0.861 to 0.963, P < 0.001). These results identify on-treatment biomarker trajectories as robust, accessible surrogate indicators of clinical therapeutic efficacy and patient prognosis in breast cancer management.

Conclusion: Our data establish that systemic inflammatory indices function as powerful, non-invasive predictors of therapeutic response. Integrating longitudinal kinetics with baseline measurements allows clinicians to accurately stratify refractory cases and optimize personalized therapeutic strategies.

Graphical Abstract

Dynamic Changes in Inflammatory Biomarkers and Their Correlation with Therapeutic Response in Breast Cancer Patients Undergoing Chemotherapy

Keywords

Subjects

[1]       Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Seromata, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
[2]       Paluch-Shimon, S., Cardoso, F., Partridge, A. H., Abulkhair, O., Azim, H. A., Bianchi-Micheli, G., et al. (2022). ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). Annals of Oncology, 33(11), 1097–1118.
[3]       Guo, R., Si, J., Xue, J., Su, Y., Mo, M., Yang, B., et al. (2019). Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999–2017. Chinese Journal of Cancer Research, 31(4), 653–662.
[4]       Kim, J. K., Kwak, B. S., Lee, J. S., Hong, S. J., Kim, H. J., Son, B. H., et al. (2007). Do very young Korean breast cancer patients have worse outcomes? Annals of Surgical Oncology, 14(12), 3385–3391.
[5]       Yang, Y., Wei, W., Jin, L., He, H., Wei, M., Shen, S., et al. (2022). Comparison of the characteristics and prognosis between very young women and older women with breast cancer: A multi-institutional report from China. Frontiers in Oncology, 12, 783487.
[6]       Partridge, A. H., Hughes, M. E., Warner, E. T., Ottesen, R. A., Wong, Y. N., Edge, S. B., et al. (2016). Subtype-dependent relationship between young age at diagnosis and breast cancer survival. Journal of Clinical Oncology, 34(27), 3308–3314.
[7]       Li, Y., Chen, H., He, J., Fan, Z., & Zhang, H. (2023). The outcome of neoadjuvant chemotherapy and the current trend of surgical treatment in young women with breast cancer: A multicenter real-world study (CSBrS-012). Frontiers in Public Health, 11, 1100421.
[8]       Bedognetti, D., Hendrickx, W., Marincola, F. M., & Miller, L. D. (2015). Prognostic and predictive immune gene signatures in breast cancer. Current Opinion in Oncology, 27(6), 433–444.
[9]       Zheng, T., Wang, A., Hu, D., & Wang, Y. (2017). Molecular mechanisms of breast cancer metastasis by gene expression profile analysis. Molecular Medicine Reports, 16(4), 4671–4677.
[11]    Prabawa, I. P. Y., Bhargah, A., Liwang, F., Tandio, D. A., Tandio, A. L., Lestari, A. A. W., et al. (2019). Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of. Asian Pacific Journal of Cancer Prevention, 20(3), 863–868.
[12]    Guo, W., Lu, X., Liu, Q., Zhang, T., Li, P., Qiao, W., et al. (2019). Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals. Cancer Medicine, 8(9), 4135–4148.
[13]    Kubota, K., Shimizu, A., Notake, T., Masuo, H., Hosoda, K., Yasukawa, K., et al. (2022). Preoperative peripheral blood lymphocyte-to-monocyte ratio predicts long-term outcome for patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 29(2), 1437–1448.
[14]    Zhang, X., Zhao, W., Yu, Y., Qi, X., Song, L., Zhang, C., et al. (2020). Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: An updated meta-analysis. World Journal of Surgical Oncology, 18(1), 191.
[15]    Şahin, A. B., Cubukcu, E., Ocak, B., Diagonal, A., Oyucu Orhan, S., Tolunay, S., et al. (2021). Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Scientific Reports, 11(1), 14662.
[16]    Bektas, A., Schurman, S. H., Sen, R., & Ferrucci, L. (2017). Human T cell immunosenescence and inflammation in aging. Journal of Leukocyte Biology, 102(4), 977–988.
[17]    Liu, Z., Liang, Q., Ren, Y., Guo, C., Ge, X., Wang, L., et al. (2023). Immunosenescence: Molecular mechanisms and diseases. Signal Transduction and Targeted Therapy, 8(1), 200.
[18]    Singh, R., Mishra, M. K., & Aggarwal, H. (2017). Inflammation, immunity, and cancer. Mediators of Inflammation, 2017, 6027305.
[19]    Franceschi, C., Bonafè, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., et al. (2000). Inflamm-aging: An evolutionary perspective on immunosenescence. Annals of the New York Academy of Sciences, 908, 244–254.
[20]    Abdel-Rahman, O. (2018). Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Research and Treatment, 168(1), 269–275.
[21]    Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., et al. (2013). Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Annals of Oncology, 24(9), 2206–2223.
[22]    Nielsen, T. O., Leung, S. C. Y., Rimm, D. L., Dodson, A., Acs, B., Badve, S., et al. (2021). Assessment of Ki67 in breast cancer: Updated recommendations from the International Ki67 in Breast Cancer Working Group. JNCI: Journal of the National Cancer Institute, 113(7), 808–819.
[23]    Loibl, S., Jackisch, C., Lederer, B., Untch, M., Paepke, S., Kümmel, S., et al. (2015). Outcome after neoadjuvant chemotherapy in young breast cancer patients: A pooled analysis of individual patient data from eight prospectively randomized controlled trials. Breast Cancer Research and Treatment, 152(2), 377–387.
[24]    Molony, R. D., Malawista, A., & Montgomery, R. R. (2018). Reduced dynamic range of antiviral innate immune responses in aging. Experimental Gerontology, 107, 130–135.
[25]    Yanes, R. E., Gustafson, C. E., Weyand, C. M., & Goronzy, J. J. (2017). Lymphocyte generation and population homeostasis throughout life. Seminars in Hematology, 54(1), 33–38.
[26]    Masters, A. R., Haynes, L., Su, D. M., & Palmer, D. B. (2017). Immune senescence: Significance of the stromal microenvironment. Clinical and Experimental Immunology, 187(1), 6–15.
[27]    Thompson, H. L., Smithey, M. J., Surh, C. D., & Nikolich-Žugich, J. (2017). Functional and homeostatic impact of age-related changes in lymph node stroma. Frontiers in Immunology, 8, 706.